Email Updates

You are here

Home

3 JUNE 2022 VOLUME 24 ISSUE 22

Media Coverage

  • Are Youth More Afraid of Pregnancy Than HIV?

    Recently, I was having a chat with a friend involved in providing HIV/AIDS awareness and health services to young people. She told me of how surprised she was with a young girl, who had been just diagnosed with HIV, but asked her what time it took for one to not be able to transmit the virus.

    June 2, 2022
    General
    The New Times

  • Dolutegravir Resistance Showing Up After Prolonged Periods on Failing Treatment

    Dolutegravir resistance is being detected in people with HIV in Malawi who spend long periods on failing treatment and there is a pressing need for improved capacity to carry out resistance testing in sub-Saharan Africa, researchers in Malawi and South Africa report in the journal Open Forum Infectious Diseases.

    June 2, 2022
    Treatment
    aidsmap

  • 550… and Counting

    Monkeypox is a serious crisis for the LGBTQ community in the US and worldwide. And as we mobilize against the virus, we also have to realize that, as with HIV, monkeypox affects many people outside of our own circles. As we urge our national leaders to step up their response, that response has to be equitable and global. If monkeypox secures a foothold in the US, those with the least access to resources will suffer most—as is the case with almost any infection or condition that afflicts us.

    June 2, 2022
    General
    The Nation

  • America Led on Global Health Before. It Must Do So for COVID

    Almost exactly 20 years ago, President George W. Bush stood in the White House Rose Garden and announced a $500 million initiative in Africa and the Caribbean to reduce HIV transmission from women living with HIV to their newborns. The United States was already the largest donor to the newly minted Global Fund to Fight AIDS, Tuberculosis and Malaria. The new initiative further solidified America as a leading contributor to what was then the most consequential global plague. Yet Mr. Bush told aides that it wasn’t enough. He wanted to do more. Written by long-time HIV advocate/activist Emily Bass.

    June 1, 2022
    General
    The New York Times

  • There’s Still No HIV Vaccine. The Science Behind Coronavirus Shots May Help

    Kathryn Stephenson was crushed last summer when she learned that an experimental HIV vaccine she had worked on for years failed to protect young women in sub-Saharan Africa from infection. “I’m not afraid to say that I cried,” recalled Stephenson, a researcher at Beth Israel Deaconess Medical Center in Boston. The failure wasn’t personal. Over decades, nearly every idea in science has been tried in the quest for an HIV vaccine — and faltered.

    June 1, 2022
    HIV Vaccine
    The Washington Post

  • Combination Anti-HIV Antibody Infusions Suppress Virus for Prolonged Period

    Individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bnAbs), according to a small study published June 1st in the journal Nature.

    June 1, 2022
    Antibody Related Research
    POZ

  • Why We Need To Push Health Equity for LGBTI+ Communities Into the Spotlight

    Discrimination and stigma continue to fuel inequalities in health care among sexual and gender minority groups. Shockingly, transgender people are over 13 times more likely to develop HIV than any other populations. Policy barriers and inadequate health care services continue to place these groups at high risk of acquiring HIV, despite over 40 years of progress, an issue reinforced by a landmark study on health equity.

    June 1, 2022
    General
    POLITICO

  • Over 3 Million People on New HIV Drug, but Not All Smooth Sailing

    The introduction of the antiretroviral drug dolutegravir arguably represents the biggest advance in HIV treatment in the last decade. Dolutegravir is highly effective at suppressing HIV in the body, it has fewer side effects than the drugs it is replacing, and HIV struggles to become resistant to it. It is also cheap.

    May 31, 2022
    Treatment
    Spotlight

  • GSK’s ViiV Adds a New, Unexpected Demographic to Dovato Campaign

    Ann Edwards looks exactly like what she is—a loving wife, mother and grandmother—a retired school administrator living in Connecticut. She is also an HIV patient taking GSK ViiV’s Dovato.

    May 31, 2022
    Treatment
    Fierce Pharma

  • To Fight Monkeypox, Remember the Lessons of COVID and HIV

    As public health experts and advocates, we are concerned about how far monkeypox has spread around the world. The lack of easy testing and surveillance makes the size of the outbreak difficult to estimate. As queer men from the United States and South Africa, we are also concerned for our communities. Much, though not all, of the spread outside the regions where monkeypox is more common has been among men who have sex with men.

    May 29, 2022
    General
    The New York Times

  • Ingestible Sensor Helps Identify PrEP Adherence Patterns

    PrEP pills combined with an ingestible sensor can identify patients who are adherent to the medication and those who are not, according to a study. “Our group had worked with the ingestible sensor system in tuberculosis treatment. As academic clinicians involved in clinical trials, we were impressed by how safe and accurate the technology was,” Sara H. Browne, MD, clinical professor of medicine at the University of California, San Diego School of Medicine, told Healio.

    May 29, 2022
    PrEP
    Healio

  • Gay Men Need a Specific Warning About Monkeypox

    A disproportionate number of cases in the recent monkeypox outbreak have shown up among gay and bisexual men. And as public-health authorities investigate possible links to sexual or other close physical contact at a Pride event in the Canary Islands, a sauna in Madrid, and other gay venues in Europe, government officials are trying hard not to single out a group that endured terrible stigma at the height of America’s AIDS crisis.

    May 28, 2022
    General
    The Atlantic

  • ViiV Will Make It Easier for Generic Companies to Copy Its HIV Prevention Shot, but It’s Not Clear When

    In response to criticism, ViiV Healthcare has agreed to license its long-acting injectable HIV prevention shot to the Medicines Patent Pool so that generic companies can make and distribute less expensive versions to low- and middle-income countries. But the move met with mixed reactions, due to the timetable and current pricing for the medication.

    May 27, 2022
    PrEP
    STAT

Published Research

Announcements